Sena Garber

1.2k total citations
23 papers, 1.1k citations indexed

About

Sena Garber is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Sena Garber has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Infectious Diseases, 18 papers in Virology and 9 papers in Molecular Biology. Recurrent topics in Sena Garber's work include HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (18 papers) and HIV/AIDS Research and Interventions (8 papers). Sena Garber is often cited by papers focused on HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (18 papers) and HIV/AIDS Research and Interventions (8 papers). Sena Garber collaborates with scholars based in United States, Germany and New Zealand. Sena Garber's co-authors include Lee T. Bacheler, Susan Erickson‐Viitanen, Carol Reid, Beverly C. Cordova, Ronald M. Klabe, Dean L. Winslow, George L. Trainor, Elizabeth D. Anton, Soo S. Ko and Michaël Otto and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and Journal of Medicinal Chemistry.

In The Last Decade

Sena Garber

23 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sena Garber United States	17	563	496	431	340	95	23	1.1k
Beverly C. Cordova United States	20	557 1.0×	499 1.0×	889 2.1×	526 1.5×	142 1.5×	34	1.8k
Karl Grozinger United States	14	770 1.4×	619 1.2×	664 1.5×	439 1.3×	57 0.6×	34	1.4k
James P. Guare United States	14	432 0.8×	369 0.7×	546 1.3×	425 1.3×	25 0.3×	32	1.1k
Jayaram R. Tagat United States	18	541 1.0×	771 1.6×	271 0.6×	409 1.2×	53 0.6×	29	1.4k
Kouichi Sekiya Japan	17	836 1.5×	591 1.2×	741 1.7×	372 1.1×	44 0.5×	25	1.5k
Cheng-Kon Shih United States	13	681 1.2×	595 1.2×	348 0.8×	337 1.0×	63 0.7×	16	1.1k
Kurt Weaver United States	15	770 1.4×	645 1.3×	245 0.6×	557 1.6×	41 0.4×	17	1.2k
Björn Classon Sweden	21	370 0.7×	201 0.4×	763 1.8×	727 2.1×	45 0.5×	67	1.3k
Blanda Stammen United Kingdom	12	505 0.9×	653 1.3×	273 0.6×	420 1.2×	27 0.3×	15	1.4k
James A. Nieman Canada	18	293 0.5×	217 0.4×	448 1.0×	392 1.2×	28 0.3×	28	1.1k

Countries citing papers authored by Sena Garber

Since Specialization

Citations

This map shows the geographic impact of Sena Garber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sena Garber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sena Garber more than expected).

Fields of papers citing papers by Sena Garber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sena Garber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sena Garber. The network helps show where Sena Garber may publish in the future.

Co-authorship network of co-authors of Sena Garber

This figure shows the co-authorship network connecting the top 25 collaborators of Sena Garber. A scholar is included among the top collaborators of Sena Garber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sena Garber. Sena Garber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kaltenbach, Robert F., Mona Patel, Robert E. Waltermire, et al.. (2003). Synthesis, antiviral activity and pharmacokinetics of P1/P1′ substituted 3-aminoindazole cyclic urea HIV protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(4). 605–608. 24 indexed citations

Geleziunas, Romas, Karen Gallagher, Hangchun Zhang, et al.. (2003). HIV-1 Resistance Profile of the Novel Nucleoside Reverse Transcriptase Inhibitor β-D-2′,3′-Dideoxy-2′,3′-Didehydro-5-Fluorocytidine (Reverset™). Antiviral chemistry & chemotherapy. 14(1). 49–59. 29 indexed citations

Schinazi, Raymond F., John W. Mellors, Holly Bazmi, et al.. (2002). DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants. Antimicrobial Agents and Chemotherapy. 46(5). 1394–1401. 39 indexed citations

Sieburth, Scott McN., Athanasios Glekas, George L. Trainor, et al.. (2001). Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. Chemistry & Biology. 8(12). 1161–1166. 67 indexed citations

Corbett, Jeffrey W., Jay A. Markwalder, Beverly C. Cordova, et al.. (2001). 3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry Letters. 11(2). 211–214. 10 indexed citations

Kaltenbach, Robert F., George L. Trainor, Daniel P. Getman, et al.. (2001). DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants. Antimicrobial Agents and Chemotherapy. 45(11). 3021–3028. 8 indexed citations

Corbett, Jeffrey W., Soo S. Ko, James D. Rodgers, et al.. (2000). Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry. 43(10). 2019–2030. 272 indexed citations

Rodgers, James D., Patrick Y. S. Lam, Barry L. Johnson, et al.. (1998). Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. Chemistry & Biology. 5(11). R312–R312. 1 indexed citations

Patel, Mona, Robert F. Kaltenbach, David A. Nugiel, et al.. (1998). The synthesis of symmetrical and unsymmetrical P1/P1′ cyclic ureas as HIV protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 8(9). 1077–1082. 19 indexed citations

10.

Rodgers, James D., Patrick Y. S. Lam, Haisheng Wang, et al.. (1998). Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. Chemistry & Biology. 5(10). 597–608. 32 indexed citations

11.

Lucca, George V. De, Jing Liang, Beverly C. Cordova, et al.. (1998). Nonsymmetric P2/P2‘ Cyclic Urea HIV Protease Inhibitors. Structure−Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 Analogues. Journal of Medicinal Chemistry. 41(13). 2411–2423. 43 indexed citations

12.

Garber, Sena. (1997). Altered gap junctional intercellular communication in neoplastic rat esophageal epithelial cells. Carcinogenesis. 18(6). 1149–1153. 17 indexed citations

13.

Nugiel, David A., Lyndon A. M. Cornelius, Chong‐Hwan Chang, et al.. (1997). Improved P1/P1‘ Substituents for Cyclic Urea Based HIV-1 Protease Inhibitors: Synthesis, Structure−Activity Relationship, and X-ray Crystal Structure Analysis. Journal of Medicinal Chemistry. 40(10). 1465–1474. 23 indexed citations

14.

Winslow, Dean L., Sena Garber, Carol Reid, et al.. (1996). Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS. 10(11). 1205–1209. 44 indexed citations

15.

Aldrich, Paul E., Lee T. Bacheler, Chong‐Hwan Chang, et al.. (1996). Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chemistry & Biology. 3(4). 301–314. 119 indexed citations

16.

King, Robert W., et al.. (1995). Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. Antiviral Research. 28(1). 13–24. 25 indexed citations

17.

King, Robert W., Sena Garber, Dean L. Winslow, et al.. (1995). Multiple Mutations in the Human Immunodeficiency Virus Protease Gene Are Responsible for Decreased Susceptibility to Protease Inhibitors. Antiviral chemistry & chemotherapy. 6(2). 80–88. 27 indexed citations

18.

Baur, Andreas S., Sena Garber, & B. Matija Peterlin. (1994). Effects of CD45 on NF-kappa B. Implications for replication of HIV-1.. The Journal of Immunology. 152(3). 976–983. 15 indexed citations

19.

Garber, Sena, Dean L. Winslow, Carol Reid, et al.. (1993). In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.. Proceedings of the National Academy of Sciences. 90(16). 7543–7547. 114 indexed citations

20.

Reid, Carol, et al.. (1993). XM323, a novel non-peptidyl inhibitor of HIV protease with potent in vitro antiviral activity. 34. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact